We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

151 hedge funds and large institutions have $827M invested in Revance Therapeutics, Inc. in 2021 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 56 increasing their positions, 41 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 41

20% more call options, than puts

Call options by funds: $11.7M | Put options by funds: $9.78M

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

8% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 37

4% less funds holding

Funds holding: 158 → 151 (-7)

44% less capital invested

Capital invested by funds: $1.48B → $827M (-$650M)

Holders
151
Holders Change
-7
Holders Change %
-4.43%
% of All Funds
2.32%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
34
Increased
56
Reduced
41
Closed
37
Calls
$11.7M
Puts
$9.78M
Net Calls
+$1.96M
Net Calls Change
+$5.27M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$30.7M
2
HM
HealthCor Management
New York
+$22.8M
3
PAI
Palo Alto Investors
California
+$19.5M
4
Capital World Investors
Capital World Investors
California
+$12.4M
5
PCH
Polar Capital Holdings
United Kingdom
+$8.61M

Top Sellers

Rank Fund Capital Flow
1
ACH
ArrowMark Colorado Holdings
Colorado
-$78.2M
2
AllianceBernstein
AllianceBernstein
Tennessee
-$52.3M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$25.2M
4
Principal Financial Group
Principal Financial Group
Iowa
-$11.5M
5
DCM
Driehaus Capital Management
Illinois
-$10.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
PPA
26
Parametric Portfolio Associates
Washington
$6M +$1.64M +98,664 +37%
Walleye Capital
27
Walleye Capital
New York
$5.83M +$5.05M +302,760 +556%
RCAMU
28
Rothschild & Co Asset Management US
Connecticut
$4.72M -$253K -15,148 -5%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$4.51M +$94.9K +5,691 +2%
ETCM
30
Evolutionary Tree Capital Management
Virginia
$4.06M +$1.36M +81,342 +49%
Jacobs Levy Equity Management
31
Jacobs Levy Equity Management
New Jersey
$3.84M +$3.93M +235,524 New
Voloridge Investment Management
32
Voloridge Investment Management
Florida
$3.58M +$3.65M +219,043 New
GIM
33
Granahan Investment Management
Massachusetts
$3.53M +$1.47M +88,258 +69%
Wells Fargo
34
Wells Fargo
California
$2.78M -$5.39M -323,145 -65%
Swiss National Bank
35
Swiss National Bank
Switzerland
$2.44M – – –
AllianceBernstein
36
AllianceBernstein
Tennessee
$2.35M -$52.3M -3,137,848 -96%
Dimensional Fund Advisors
37
Dimensional Fund Advisors
Texas
$2.15M +$147K +8,801 +7%
EIM
38
Essex Investment Management
Massachusetts
$2.11M -$32.4K -1,941 -1%
Ameriprise
39
Ameriprise
Minnesota
$1.98M -$742K -44,531 -27%
Assenagon Asset Management
40
Assenagon Asset Management
Luxembourg
$1.94M +$1.98M +118,864 New
JMPWA
41
JP Morgan Private Wealth Advisors
California
$1.83M -$878K -52,662 -32%
Bank of America
42
Bank of America
North Carolina
$1.82M +$684K +41,017 +58%
Barclays
43
Barclays
United Kingdom
$1.78M +$1.11M +66,851 +159%
AC
44
Antara Capital
New York
$1.63M +$1.67M +100,000 New
HWAM
45
Hennion & Walsh Asset Management
New Jersey
$1.57M -$147K -8,824 -8%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$1.57M +$41.5K +2,490 +3%
State of Wisconsin Investment Board
47
State of Wisconsin Investment Board
Wisconsin
$1.45M – – –
Two Sigma Investments
48
Two Sigma Investments
New York
$1.45M +$1.48M +88,806 New
Prudential Financial
49
Prudential Financial
New Jersey
$1.41M -$13.3K -795 -0.9%
CS
50
Credit Suisse
Switzerland
$1.39M -$18.1K -1,086 -1%
1
2
3 4 5

RVNC Hedge Fund Activity: Q4 2021 in Review

151 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2021, worth a combined $827M — down 44% from $1.48B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of RVNC and 34 opened new positions — a net loss of 3 holders — while 41 trimmed existing stakes and 56 added.

The largest buyer was JP Morgan Chase, adding an estimated $30.7M. The largest seller was ArrowMark Colorado Holdings, exiting entirely with an estimated $78.2M sold.

  • 151 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2021, down from 158 in Q3 2021.
  • Funds reported $827M of Revance Therapeutics, Inc. stock for Q4 2021, down 44% quarter-over-quarter.
  • 34 funds opened new Revance Therapeutics, Inc. positions in Q4 2021 and 37 closed out, a net change of -3 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q4 2021 was JP Morgan Chase, an estimated $30.7M added.
  • The largest Revance Therapeutics, Inc. seller in Q4 2021 was ArrowMark Colorado Holdings, an estimated $78.2M sold.

Based on aggregated 13F filings for Q4 2021.